Affiliation:
1. School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
Abstract
This review clarifies the evolution of PD-L1 inhibitors and provides insights into the current development of PD-L1 inhibitors, especially targeting internalization and degradation of PD-L1.
Funder
National Natural Science Foundation of China
China Postdoctoral Science Foundation
Government of Jiangsu Province
Publisher
Royal Society of Chemistry (RSC)
Subject
Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry